Corbus Pharmaceuticals (NASDAQ:CRBP) Rating Reiterated by Mizuho

Corbus Pharmaceuticals (NASDAQ:CRBP)‘s stock had its “outperform” rating reaffirmed by stock analysts at Mizuho in a report issued on Friday, Benzinga reports. They presently have a $74.00 price target on the biopharmaceutical company’s stock. Mizuho’s price objective indicates a potential upside of 243.87% from the stock’s current price.

CRBP has been the subject of a number of other reports. Lifesci Capital raised Corbus Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, August 21st. Oppenheimer increased their price target on shares of Corbus Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a research note on Wednesday, August 7th. Royal Bank of Canada restated an “outperform” rating and issued a $82.00 price objective on shares of Corbus Pharmaceuticals in a research report on Friday. B. Riley assumed coverage on Corbus Pharmaceuticals in a report on Wednesday, June 26th. They set a “buy” rating and a $85.00 price objective on the stock. Finally, Wedbush lowered their target price on Corbus Pharmaceuticals from $85.00 to $51.00 and set an “outperform” rating for the company in a research note on Friday. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $72.29.

Corbus Pharmaceuticals Price Performance

Shares of CRBP traded down $30.18 during trading hours on Friday, hitting $21.52. The stock had a trading volume of 7,946,569 shares, compared to its average volume of 539,400. The stock has a market capitalization of $229.98 million, a price-to-earnings ratio of -3.09 and a beta of 2.56. The company’s fifty day moving average is $55.82 and its two-hundred day moving average is $47.05. Corbus Pharmaceuticals has a 52 week low of $3.03 and a 52 week high of $61.90.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.19) by $0.29. Equities analysts predict that Corbus Pharmaceuticals will post -3.77 EPS for the current fiscal year.

Institutional Trading of Corbus Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in CRBP. Bank of New York Mellon Corp bought a new position in shares of Corbus Pharmaceuticals in the 2nd quarter worth $1,368,000. Janus Henderson Group PLC acquired a new position in Corbus Pharmaceuticals in the first quarter valued at about $13,363,000. Price T Rowe Associates Inc. MD acquired a new position in Corbus Pharmaceuticals in the first quarter valued at about $7,554,000. Acadian Asset Management LLC bought a new position in Corbus Pharmaceuticals during the second quarter worth about $716,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Corbus Pharmaceuticals during the 1st quarter worth about $976,000. Institutional investors own 64.64% of the company’s stock.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.